Spark Therapeutics reports disappointing results

Spark Therapeutics Inc. (Nasdaq: ONCE) reported disappointing preliminary results from a Phase 1/2 clinical trial of SPK-8011 to treat hemophilia A sending the stock price plummeting $25.66 to close at $47.72.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.